Prof. Sieber’s (b. 1976) research field is bioorganic chemistry. The aim of his work is to develop new drugs for multidrug-resistant bacteria. His research is based on methods which combine synthetic chemistry, functional proteomics, cell biology and mass spectrometry. This approach enables the discovery of new active substances, some of which are currently being optimized for medical application. Prof. Sieber studied chemistry at the University of Marburg and completed his doctorate at the laboratories of Prof. C. T. Walsh at the Harvard Medical School and Prof. M. Marahiel at the University of Marburg (2004). He did postdoctoral research at the Scripps Institute in La Jolla, California, under Prof. B. F. Cravatt (2006). After that, he undertook independent research at Munich’s Ludwig Maximilian University with the assistance of an Emmy Noether scholarship from the German Research Foundation. In 2009, he was appointed to the Chair of Organic Chemistry II at TUM. In 2010, he received an ERC starting grant and EXIST start-up support for the company AVIRU GmbH, which was established based on his research.